Jan Panteli Email Address

Associate Director, Upstream Process Development, Gene Therapy

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

Bioprocess/chemical engineer with background in cell culture, molecular biology, cancer, microscopy, and data analysis. Currently at Ultragenyx Pharmaceuticals (formerly Dimension Therapeutics) working on upstream bioprocess scale-up and process development for rare disease AAV gene therapies.